Viridian Q3 2026 Earnings: Lumvoa Launch Generates $24.7 Million

Viridian Therapeutics (Nasdaq: VRDN) reported Q3 2026 total revenue of $25.8 million, down from $70.6 million a year earlier, while basic and diluted net loss per common share widened to $0.81 from $0.34. The quarter ended September 30, 2026, and the main operating development was Lumvoa’s first commercial quarter, which produced $24.7 million in net product revenue and had more than 100 patients on therapy by quarter-end. Higher commercial spending outweighed lower R&D expense, widening the net loss to $101.2 million.

Core Financial Results

The year-over-year revenue comparison was not like-for-like. Q3 2025 included $70.0 million of license revenue and no product revenue, while Q3 2026 included $24.7 million from Lumvoa, $125,000 of license revenue, and $956,000 of collaboration revenue.

Operating expenses increased to $129.2 million from $110.6 million. Lower clinical study spending reduced R&D expense, but this was more than offset by the expansion in SG&A associated with Lumvoa’s commercialization and a larger organization.

Business and Product Performance

Lumvoa Establishes a Commercial Revenue Base

Lumvoa, also known as veligrotug-vvze, generated $24.7 million of net product revenue during its first commercial quarter. More than 100 patients were receiving the therapy for thyroid eye disease at September 30, and management reported progress in market access and patient services.

The Centers for Medicare & Medicaid Services assigned Lumvoa permanent J-code J3242, effective January 1, 2027. Management described the early launch as exceeding its expectations, although the product remains at an early stage of adoption.

Elegrobart and Pipeline Milestones

Viridian expects to submit a Biologics License Application for elegrobart in thyroid eye disease during Q1 2027. If approved, the company plans to offer the subcutaneous therapy in an autoinjector with at-home dosing every four or eight weeks. Viridian expects its existing Lumvoa commercial and medical infrastructure to support a potential launch with limited incremental investment.

Other scheduled pipeline developments include:

• VRDN-008 Phase 1 healthy-volunteer data and an FcRn portfolio development update in Q4 2026.
• Initiation of a VRDN-292 Phase 1 trial in Graves’ disease patients in Q4 2026.
• Continued development of VRDN-006 following Phase 1 results that showed class-consistent IgG reductions, preservation of albumin and LDL, and generally favorable tolerability.

Profitability and Balance Sheet

R&D expense declined because of lower costs for veligrotug and elegrobart clinical studies. That reduction was partially offset by additional investment in the TSHR and FcRn programs and higher personnel costs.

SG&A expense more than doubled as Viridian added personnel and professional services to support Lumvoa’s commercial launch and its growing organization. The increase of approximately $33.3 million in SG&A was larger than the approximately $16.2 million reduction in R&D, contributing to the wider operating loss.

Cash, cash equivalents, and marketable securities totaled $955.2 million at September 30, 2026, up approximately $80.6 million from December 31, 2025. Accounts receivable increased from zero at year-end to $29.8 million, while total liabilities rose to $448.0 million from $177.3 million and stockholders’ equity declined to $580.7 million from $722.2 million.

Management expects existing cash and anticipated future commercial revenue from Lumvoa and, if approved, elegrobart to fund its current business plans through profitability. That assessment explicitly depends on future product revenue and the successful approval and commercialization of elegrobart.

Lumvoa Changed the Revenue Mix but Not Yet the Loss Profile

Lumvoa represented approximately 95.8% of total Q3 revenue, marking a clear shift from reliance on license and collaboration revenue toward product sales. However, combined R&D and SG&A expenses were approximately $127.7 million, more than five times Lumvoa’s quarterly product revenue. These expenses support both commercialization and multiple development programs, so the comparison is not a product-level profitability measure, but it illustrates the scale Lumvoa must achieve before the company’s loss profile can materially change.

The prior-year license payment also makes the headline revenue decline less informative about commercial execution. The more relevant operating indicators for upcoming quarters will be Lumvoa patient adoption, market access progress, and the relationship between product revenue growth and the commercial cost base.

Recent Insider Transactions

The supplied six-month insider summary reported 1,226,470 shares purchased across three transactions and 14,212 shares sold in one transaction, resulting in net purchases of 1,212,258 shares. The following table includes the latest supplied records with a clearly identified transaction and reported amount.

Tousignant’s August records included both a derivative security conversion and a same-day sale. The largest disclosed transaction was Fairmount Funds Management’s approximately $20.0 million indirect purchase. These records do not, by themselves, establish the participants’ views on Viridian’s outlook.

Risks Investors Need to Watch

• Lumvoa remains early in its launch: Viridian has a limited history of product sales, and future revenue depends on continued patient adoption, market access, manufacturing, and commercial execution.
• The cost base remains high: Commercial expansion pushed SG&A sharply higher, while R&D spending remained substantial across several programs. Slower product growth would prolong operating losses.
• Elegrobart is still subject to regulatory risk: The planned Q1 2027 BLA submission does not ensure approval or commercialization, yet management’s funding assessment includes anticipated elegrobart revenue if approved.
• Upcoming pipeline milestones carry execution and data risk: VRDN-008 data and the planned VRDN-292 trial could affect development priorities, and early or preliminary findings may not predict later clinical results.

Summary

Viridian’s Q3 2026 results marked its transition to a commercial-stage biotechnology company, with Lumvoa establishing a meaningful product revenue base. That progress did not yet offset the commercial cost buildout and ongoing pipeline investment, while the prior-year license payment complicated the headline revenue comparison. The next operating indicators are Lumvoa adoption and market access, followed by the elegrobart BLA submission and upcoming VRDN-008 and VRDN-292 milestones.